MCID: CTR002
MIFTS: 62

Cataract

Categories: Eye diseases, Fetal diseases, Genetic diseases, Metabolic diseases, Nephrological diseases, Neuronal diseases, Oral diseases, Rare diseases

Aliases & Classifications for Cataract

Summaries for Cataract

KEGG : 37
Cataracts can be defined as any opacity of the crystalline lens, often associated with breakdown of the lens microarchitecture, possibly including vacuole formation and disarray of lens cells, which can cause large fluctuations in density resulting in light scattering. In addition, light scattering and opacity will occur if there is a significant amount of high molecular weight protein aggregates. Cataracts can be classified by the age at onset: a congenital or infantile cataract presents within the first year of life; a juvenile cataract presents within the first decade of life; a presenile cataract presents before the age of about 45 years, and senile or age-related cataract after that. Congenital cataracts are a major cause of induced blindness in children, and inherited cataracts are the major cause of congenital cataracts. Inherited congenital cataracts have been associated with mutations in specific genes, including those of crystallins, gap junction proteins, membrane transport and channel proteins, the cytoskeleton, and growth and transcription factors. Inherited congenital cataracts may be inherited as autosomal dominant (most frequent), autosomal recessive, or X-linked traits.

MalaCards based summary : Cataract, also known as cataracts, is related to cataract 16, multiple types and cataract 10, multiple types. An important gene associated with Cataract is LIM2 (Lens Intrinsic Membrane Protein 2), and among its related pathways/superpathways is Protein processing in endoplasmic reticulum. The drugs Ketorolac and Tropicamide have been mentioned in the context of this disorder. Affiliated tissues include Eye, eye and endothelial, and related phenotype is vision/eye.

Disease Ontology : 12 A lens disease characterized by clouding of the lens inside the eye which leads to a decrease in vision.

MedlinePlus : 43 A cataract is a clouding of the lens in your eye. It affects your vision. Cataracts are very common in older people. By age 80, more than half of all Americans either have a cataract or have had cataract surgery. A cataract can occur in either or both eyes. It cannot spread from one eye to the other. Common symptoms are Blurry vision Colors that seem faded Glare - headlights, lamps or sunlight may seem too bright. You may also see a halo around lights. Not being able to see well at night Double vision Frequent prescription changes in your eye wear Cataracts usually develop slowly. New glasses, brighter lighting, anti-glare sunglasses or magnifying lenses can help at first. Surgery is also an option. It involves removing the cloudy lens and replacing it with an artificial lens. Wearing sunglasses and a hat with a brim to block ultraviolet sunlight may help to delay cataracts. NIH: National Eye Institute

PubMed Health : 63 About cataracts: A cataract is an eye condition in which the lens of the eye becomes cloudy. This causes vision to worsen, making it especially difficult to see fine details clearly. Some people’s vision is only slightly affected, whereas others might lose their eyesight very quickly. How it progresses will depend on things like the exact type of cataract. The word “cataract” comes from the Greek word for “waterfall” because in the past it was believed that the blurring was caused by a fluid in the eye. Cataracts mostly affect people over 50, and the risk increases with age: About 20 out of 100 people between the ages of 65 and 74 have a cataract. And more than 50 out of 100 people over the age of 74 are affected. Cataracts are the main cause of blindness in developing countries. The number of people who go blind from cataracts is considerably lower in industrialized countries due to the availability of effective surgery. Cataract surgery involves removing the cloudy eye lens and replacing it with an artificial lens. It is one of the most common surgical procedures performed in Germany, where about 800,000 people have cataract surgery every year.

Wikipedia : 75 A cataract is a clouding of the lens in the eye which leads to a decrease in vision. Cataracts often... more...

Related Diseases for Cataract

Diseases in the Cataract family:

Cataract 32, Multiple Types Cataract 7
Cataract 8, Multiple Types Cataract 4, Multiple Types
Cataract 29 Cataract 42
Cataract 20, Multiple Types Cataract 1, Multiple Types
Cataract 30, Multiple Types Cataract 41
Cataract 6, Multiple Types Cataract 5, Multiple Types
Cataract 46, Juvenile-Onset Cataract 40
Cataract 10, Multiple Types Cataract 24
Cataract 3, Multiple Types Cataract 14, Multiple Types
Cataract 9, Multiple Types Cataract 2, Multiple Types
Cataract 31, Multiple Types Cataract 25
Cataract 26, Multiple Types Cataract 27
Cataract 28 Cataract 35
Cataract 22, Multiple Types Cataract 18
Cataract 21, Multiple Types Cataract 23, Multiple Types
Cataract 11, Multiple Types Cataract 33, Multiple Types
Cataract 17, Multiple Types Cataract 12, Multiple Types
Cataract 47 Cataract 34, Multiple Types
Cataract 16, Multiple Types Cataract 36
Cataract 37 Cataract 38
Cataract 39, Multiple Types Cataract 15, Multiple Types
Cataract 19, Multiple Types Cataract 43
Cataract 44 Cataract 45
Cataract 48 Cataract 30
Cataract 33 Cataract Congenital Autosomal Dominant
Cataract, Total Congenital

Diseases related to Cataract via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1654)
# Related Disease Score Top Affiliating Genes
1 cataract 16, multiple types 35.4 HSF4 GJA3 CRYGS CRYGD CRYBA1 CRYAB
2 cataract 10, multiple types 35.3 CRYBA1 CRYAB
3 cataract 44 35.2 LIM2 HSF4 GJA8 CRYAA
4 cataract 9, multiple types 35.2 GJA8 CRYAA
5 cataract 30, multiple types 35.2 GJA8 GJA3 CRYGD
6 cataract 1, multiple types 35.2 GJA8 GJA3
7 cataract 24 35.2 CTAA2 CRYBB3 CRYAA
8 cataract microcornea syndrome 35.1 GJA8 CRYGD CRYAA
9 cataract 25 35.1 GJA8 CTRCT25 CRYGS CRYBA1
10 nuclear senile cataract 35.1 CRYGS CRYGD CRYAA
11 posterior polar cataract 35.0 GJA3 CRYGD CRYBA1 CRYAB
12 cerulean cataract 35.0 CTRCT37 CRYGD
13 mature cataract 34.9 CRYGS CRYAA
14 cataract 14, multiple types 34.8 GJA8 GJA3
15 early-onset nuclear cataract 34.7 GJA8 GJA3 CRYGD CRYBB3 CRYBA1 CRYAB
16 warburg micro syndrome 33.0 IARS2 CRYBB3
17 lens disease 32.5 GJA8 GJA3 CRYGS CRYGD CRYAB CRYAA
18 presbyopia 31.8 CRYGS CRYAA
19 hyperferritinemia with or without cataract 12.7
20 cataract 4, multiple types 12.7
21 cataract 21, multiple types 12.7
22 cataract 6, multiple types 12.6
23 cataract 3, multiple types 12.6
24 cataract 22, multiple types 12.6
25 cataract 11, multiple types 12.6
26 cataract 17, multiple types 12.6
27 cataract 2, multiple types 12.6
28 cataract 40 12.6
29 cataract 5, multiple types 12.6
30 cataract 18 12.6
31 cataract 23, multiple types 12.6
32 cataract 31, multiple types 12.6
33 cataract 34, multiple types 12.6
34 cataract 8, multiple types 12.6
35 cataract 7 12.5
36 cataract 38 12.5
37 cataract 41 12.5
38 cataract 39, multiple types 12.5
39 cataract 32, multiple types 12.5
40 cataract 46, juvenile-onset 12.5
41 congenital cataracts, facial dysmorphism, and neuropathy 12.5
42 cataract 26, multiple types 12.5
43 cataract 12, multiple types 12.5
44 senile cataract 12.5
45 cataract 19, multiple types 12.5
46 cataract 15, multiple types 12.5
47 diabetic cataract 12.5
48 cataract 47 12.5
49 cataract 13 with adult i phenotype 12.5
50 cataract 30 12.5

Graphical network of the top 20 diseases related to Cataract:



Diseases related to Cataract

Symptoms & Phenotypes for Cataract

MGI Mouse Phenotypes related to Cataract:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 vision/eye MP:0005391 9.28 CRYAB CRYBA1 CRYGD CRYGS GJA3 GJA8

Drugs & Therapeutics for Cataract

PubMed Health treatment related to Cataract: 63

Some people can compensate for the vision loss, temporarily or even in the longer term, by wearing glasses or contact lenses. There are no medications for the treatment of cataracts. The only effective treatment is surgery. Cataract surgery involves removing the cloudy lens and replacing it with a new, artificial lens. The lens capsule – an elastic membrane surrounding the lens of the eye – is left in the eye during surgery. Only the inner core and the outer cortex of the lens are broken up into small pieces using ultrasound. The pieces are then sucked out of the eye through a small cut. This procedure, called phacoemulsification, is the standard technique in Germany and some other countries. Once the lens has been removed, an artificial lens is implanted into the lens capsule. Whether and when surgery is an appropriate treatment option is very much a personal decision. The extent to which vision loss is affecting someone’s life will play a very important role. Another factor to consider is the presence of other (eye) conditions, which could affect the outcome of cataract surgery.

Drugs for Cataract (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 470)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
2
Tropicamide Approved, Investigational Phase 4 1508-75-4 5593
3
Nitric Oxide Approved Phase 4 10102-43-9 145068
4
Cefazolin Approved Phase 4 25953-19-9 656510 33255
5
Isosorbide Dinitrate Approved, Investigational Phase 4 87-33-2 6883
6
AT-101 Approved, Investigational Phase 4 90141-22-3, 652-67-5 12597
7
Alogliptin Approved Phase 4 850649-61-5 11450633
8
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
9
Besifloxacin Approved Phase 4 141388-76-3
10
Dinoprostone Approved Phase 4 363-24-6 5280360
11
Nepafenac Approved, Investigational Phase 4 78281-72-8 151075
12
Povidone Approved Phase 4 9003-39-8
13
Bromfenac Approved Phase 4 91714-94-2 60726
14
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
15
Indomethacin Approved, Investigational Phase 4 53-86-1 3715
16
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
17
Ofloxacin Approved Phase 4 82419-36-1 4583
18
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
19
Loteprednol Approved, Experimental Phase 4 129260-79-3, 82034-46-6 444025 9865442
20
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
21
Dalteparin Approved Phase 4 9005-49-6
22
Enoxaparin Approved Phase 4 9005-49-6 772
23 Orange Approved Phase 4
24
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
25
Azithromycin Approved Phase 4 83905-01-5 447043 55185
26
Homatropine Approved Phase 4 87-00-3
27
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
28
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
29
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
30
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
31
Ethanol Approved Phase 4 64-17-5 702
32
Fluorometholone Approved, Investigational Phase 4 426-13-1 9878
33
Cocaine Approved, Illicit Phase 4 50-36-2 446220 5760
34
Budesonide Approved Phase 4 51333-22-3 63006 5281004
35
Atracurium Approved, Experimental, Investigational Phase 4 64228-79-1 47319
36
Basiliximab Approved, Investigational Phase 4 152923-56-3, 179045-86-4
37
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
38
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
39
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
40
Polyestradiol phosphate Approved Phase 4 28014-46-2
41
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
42
Gatifloxacin Approved, Investigational Phase 4 112811-59-3 5379
43
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
44
Bimatoprost Approved, Investigational Phase 4 155206-00-1 5311027
45
Latanoprost Approved, Investigational Phase 4 130209-82-4 5282380 5311221
46
Timolol Approved Phase 4 26839-75-8 33624 5478
47
Empagliflozin Approved Phase 4 864070-44-0
48
Dorzolamide Approved Phase 4 120279-96-1 3154 5284549
49
Triazolam Approved, Investigational Phase 4 28911-01-5 5556
50
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307

Interventional clinical trials:

(show top 50) (show all 1438)
# Name Status NCT ID Phase Drugs
1 Relevance of Eye Dominance in the Selection of Patients Suitable for Treatment With Monovision After Cataract Surgery Unknown status NCT01382641 Phase 4
2 Aqueous Absorption and Pharmacokinetics of Besivance Versus VIGAMOX in Patients Undergoing Phacoemulsification Unknown status NCT01296191 Phase 4 Moxifloxacin;besifloxacin
3 Effect of Posterior Corneal Toricity on Refractive Outcome of Pseudophakia Unknown status NCT01554761 Phase 4
4 A Study to Assess the Clinical Outcomes of Surgical Phaco Segmentation Techniques in Patients Undergoing Cataract Surgery Unknown status NCT02843594 Phase 4
5 Clinical Investigation of the Modified Rayner Monofocal Aspheric 600C (With Axis Marks) Intraocular Lens Unknown status NCT02378636 Phase 4
6 Efficacy of Subtenon Anesthesia With Olive Tipped Cannula: a Randomized Controlled Trial Unknown status NCT01019018 Phase 4
7 AMO's Tecnis™ Multifocal Intraocular Lenses (Tecnis MF), Alcon's ReStor Multifocal IOL Unknown status NCT01278420 Phase 4
8 Evaluation of Clinical Outcomes Following Implantation of a Sub-2mm Hydrophilic MICS Intraocular Lens Unknown status NCT01615861 Phase 4
9 Comparative Study of the Safety and Effectiveness Between Off-Label Subconjunctival Bevacizumab and Mitomycin C in Glaucoma Filtering Surgery. Unknown status NCT00468429 Phase 4 Subconjunctival Bevacizumab
10 The Effect of Pretreated Gabapentin on Hyeralgesia Occurring in the Second Operation in Staged Bilateral Cataract Surgery Unknown status NCT02127853 Phase 4 gabapentin;placebo
11 Randomized, Masked Comparison of Bromfenac and Besifloxacin BID With Either Prednisolone BID or Loteprednol 0.5% BID for Prevention of Retinal Thickening and CME Following Phacoemulsification Unknown status NCT01193504 Phase 4 Pred Forte;Lotemax
12 Clinical Evaluation of Toric Intraocular Lens Made by Aurolab Unknown status NCT01396616 Phase 4
13 Quantitative Comparison of the Efficacy of Subtenon 20-mg Triamcinolone Injection With 0.1% Dexamethasone Eye Drop in Controlling Intraocular Inflammation After Phacoemulsification Unknown status NCT01801774 Phase 4 Subtenon 20-mg triamcinolone injection;Placebo
14 Effect of Anti-inflammatory Topical Prednisolone Acetate 1%, Nepafenac of 0.1% and Ketorolac Tromethamine 0.4% in Intra-operative Mydriasis in Facetectomies Unknown status NCT00865540 Phase 4 prednisolone acetate 1%;ketorolac tromethamine 0.4%;nepafenac 0.1%;methylcellulose 0.5%
15 Combined Phacoemulsification and Glaucoma Implant Surgery Versus Combined Phacoemulsification and Trabeculectomy: A Randomized Controlled Trial Unknown status NCT00273221 Phase 4
16 Assessment in Early Changes in the Parameters of Optical Coherence Tomography (OCT Spectral Domain) in Patients With Subfoveal Neovascular Membranes Related to Age After Treatment With a Single Intravitreal Injection of Lucentis. Unknown status NCT01669447 Phase 4
17 Topical Application of ACULAR a Randomized, Vehicle Controlled Clinical Trial: Efficiency in Inhibiting Proliferative Retinopathy of Prematurity Unknown status NCT00634972 Phase 4 ACULAR;REFRESH TEARS;placebo
18 Cefazolin-Lidocaine Solution for Reducing Pain Associated With Subconjunctival Antibiotic Prophylaxis in Vitreo-Retinal Surgery Unknown status NCT02324166 Phase 4 Cefazolin;Lidocaine
19 EFFECTS OF IMMEDIATE ARGON LASER PERIPHERAL IRIDOPLASTY Versus CONVENTIONAL SYSTEMIC MEDICAL THERAPY ON OPTIC NERVE HEAD STRUCTURE AND FUNCTION OF ACUTE PRIMARY ANGLE CLOSURE EYES Unknown status NCT00485238 Phase 4 Intravenous acetazolamide
20 Pilot Study of Prevention Myopia in Children With Low Concentration of Atropine Unknown status NCT00541177 Phase 4 atropine;tropicamide
21 Effects of Ranibizumab to Delay or Regression Non-proliferative Diabetic Retinopathy(NPDR) With DME Assessed by Microaneurysm Changes: A Pilot Study Unknown status NCT02834663 Phase 4 Lucentis
22 Influence of Nitrates on Bone Remodeling and Endothelial Function in Patients With Type 2 Diabetes Mellitus. Unknown status NCT02011620 Phase 4
23 A Phase IV, Multicenter, Randomized, Active Comparator Controlled Study of the Addition of Pioglitazone Compared With Glimepiride in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Alogliptin Unknown status NCT02426294 Phase 4 Pioglitazone;Glimepiride
24 Clear Corneal Incisions and Arcuate Incisions Utilizing FemtoSecond Laser Technology for Cataract Surgery Completed NCT01383057 Phase 4
25 Laser Cataract Surgery With the Femtosecond Laser Technology Completed NCT01382823 Phase 4
26 Visual Function After Implantation of Bilateral AcrySof ReSTOR Aspheric Intraocular Lens (IOL): Postmarket Evaluation Completed NCT00818116 Phase 4
27 Dispervise Ophthalmic Viscoelastic as an Agent to Ensure Watertight Wound Closure After Clear Corneal Cataract Incisions Completed NCT01298973 Phase 4 Viscoat;Saline
28 Randomized Comparison of the Abbott WHITESTAR Signature System With Ellips Tranversal Ultrasound vs. the Alcon Infiniti With the Ozil Torsional Handpiece in Phacoemulsification: A Contralaterally-Controlled Trial Completed NCT01279031 Phase 4
29 Evaluation of the Acrysof Toric Model SN60T3 Intraocular Lens in Patients With Predicted Residual Corneal Astigmatism Between 0.75 and 1.03 Diopters (D) Completed NCT00732030 Phase 4
30 Selection of Aspheric Diffractive Multifocal IOLS Based on Corneal Wavefront Completed NCT00999492 Phase 4
31 Clinical Outcomes With AcrySof ReSTOR Aspheric Apodized Diffractive Intraocular Lens (IOL) in One Eye and a Contralateral Monofocal IOL or Phakic Eye Completed NCT00731640 Phase 4
32 A Prospective, Randomized Single-Masked Clinical Trial Comparing OCT and Visual Acuity Outcomes in Subjects Undergoing Cataract Surgery, Who Receive Xibrom Ophthalmic Solution and Standard Presurgical Care vs. Xibrom Ophthalmic Solution Plus Prednisolone Acetate 1% and Standard Presurgical Care Completed NCT00698724 Phase 4 Xibrom, and Optive;Xibrom and Pred Forte
33 Determination of Optimum Duration of Treatment With Bromfenac (Xibrom) Eyedrops Following Cataract Surgery Completed NCT00758199 Phase 4 Bromfenac;Moxifloxacin hydrochloride;Prednisolone Acetate
34 A Randomized, Masked Multi-center Safety & Efficacy Study of the Effects of Preoperative & Postoperative Cataract Surgery Use of Difluprednate Ophthalmic Emulsion, 0.05% Compared to Prednisolone Acetate Ophthalmic Suspension 1% on Visual Acuity & Corneal Edema. Completed NCT01244334 Phase 4 Difluprednate ophthalmic emulsion 0.05%;Prednisolone acetate 1%
35 A Comparison of Prostaglandin E2 (PGE2) Inhibition of Acuvail, Xibrom and Nevanac in Patients Undergoing Phacoemulsification Completed NCT01021761 Phase 4 Ketorolac Tromethamine;Bromfenac;nepafenac
36 A Comparison of Peak Aqueous Penetration of Acuvail, Xibrom, and Nevanac in Patients Undergoing Phacoemulsification Completed NCT01001806 Phase 4 Ketorolac Tromethamine 0.45%;bromfenac 0.09%;nepafenac 0.1%
37 Effect of Nepafenac on Post-operative Cystoid Macular Edema Following Uncomplicated Cataract Surgery Completed NCT00494494 Phase 4 Standard Care;nepafenac
38 Clinical Outcomes After Bilateral Implantation of ZEISS AT LISA TRI AND TRI TORIC IOL Completed NCT02770924 Phase 4
39 A Randomised Trial of Torsional Ultrasound Versus Longitudinal Ultrasound During Phacoemulsification of Age-related Cataracts: Comparison of Intra-operative Performance and Impact on Post-operative Endothelium Integrity Completed NCT01010490 Phase 4
40 Comparison of the Quality of Vision Provided by AMO Tecnis Z9000 Three-piece Silicone Posterior Chamber Intraocular Lens and Alcon Laboratories MA60 Acrysof Three-piece Acrylic Posterior Chamber Intraocular Lens Completed NCT00348270 Phase 4
41 Indomethacin Eyedrops Compared With Ketorolac Eyedrops for Ocular Inflammation Following Cataract Surgery Completed NCT00904904 Phase 4 Indomethacin ophthalmic solution;Ketorolac Ophthalmic Solution
42 Monocular Study to Evaluate the Safety and Effectiveness of the Akreos™ Toric IOL When Used to Correct Primary Aphakia With the Reduction of Astigmatism Completed NCT00825513 Phase 4
43 Parallel-group Study of Ocular Penetration of Peri-operative Topically Administered Fluoroquinolones With Cataract Surgery Completed NCT00924729 Phase 4 Moxifloxacin 0.5% ophthalmic solution;Besifloxacin 0.6% ophthalmic suspension
44 Therapeutic Variables in Cataract Surgery Completed NCT00407017 Phase 4 Gatifloxacin;Ketorolac LS;Pred Forte;Moxifloxacin;Nepafenac;EconoPred Plus
45 Pharmacokinetic Evaluation of Moxifloxacin in Vigadexa® in Aqueous Humor Samples Following Preoperative Antibiotic/Steroid Dosing in Cataract Surgery Patients Completed NCT01859702 Phase 4 Moxifloxacin 0.5%/Dexamethasone 0.1% ophthalmic solution
46 Acular LS vs. Nevanac in Post op Inflammation Following Cataract Surgery Completed NCT00348582 Phase 4 Ketorolac, Nepafenac
47 A Masked Comparison of Acular LS Plus Steroid Versus Steroid Alone for the Prevention of Macular Leakage in Cataract Patients Completed NCT00348244 Phase 4 Ketorolac, Prednisolone Acetate
48 DisCoVisc Versus Competitor Completed NCT00712244 Phase 4
49 Use of Toric Intraocular Lens to Neutralize Keratometric Astigmatism Completed NCT00925886 Phase 4
50 Visual Function With Bilateral AcrySof® ReSTOR® Aspheric SN6AD1 Completed NCT00710931 Phase 4

Search NIH Clinical Center for Cataract

Cochrane evidence based reviews: cataract

Genetic Tests for Cataract

Genetic tests related to Cataract:

# Genetic test Affiliating Genes
1 Cataract 29

Anatomical Context for Cataract

MalaCards organs/tissues related to Cataract:

41
Eye, Endothelial, Testes, Bone, Bone Marrow, Retina, Brain
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Cataract:
# Tissue Anatomical CompartmentCell Relevance
1 Eye Lens Affected by disease

Publications for Cataract

Articles related to Cataract:

(show top 50) (show all 37788)
# Title Authors PMID Year
1
Evaluating the effect of massage based on slow stroke back massage on the anxiety of candidates for cataract surgery. 38 17
31334393 2019
2
Accuracy of toric intraocular lens implantation using automated vs manual marking. 17
31376834 2019
3
Postoperative Capsular Bag Distension Syndrome - Risk Factors and Treatment. 17
31298075 2019
4
Cerebrotendinous xanthomatosis (CTX): an association of pulverulent cataracts and pseudo-dominant developmental delay in a family with a splice site mutation in CYP27A1--a case report. 9 38
20450308 2010
5
In vivo lens deficiency of the R49C alphaA-crystallin mutant. 9 38
20188090 2010
6
A novel human CRYGD mutation in a juvenile autosomal dominant cataract. 9 38
20508808 2010
7
Oxidative stress markers in patients with primary open-angle glaucoma. 9 38
20373896 2010
8
Hyperferritinaemia-cataract syndrome: worldwide mutations and phenotype of an increasingly diagnosed genetic disorder. 9 38
20511138 2010
9
HTS-Compatible Patient-Derived Cell-Based Assay to Identify Small Molecule Modulators of Aberrant Splicing in Myotonic Dystrophy Type 1. 9 38
20502647 2010
10
[Progress in pathogenic genes and their functions of congenital cataract]. 9 38
20450675 2010
11
Later retinal degeneration following childhood surgical aphakia in a family with recessive CRYAB mutation (p.R56W). 9 38
20141356 2010
12
A novel mutation in the major intrinsic protein (MIP) associated with autosomal dominant congenital cataracts in a Chinese family. 9 38
20361015 2010
13
Megakaryocyte and platelet abnormalities in a patient with a W33C mutation in the conserved SH3-like domain of myosin heavy chain IIA. 9 38
19967157 2009
14
[Hereditary hyperferritinemia cataract syndrome--the first family in Germany]. 9 38
19994473 2009
15
A novel GJA8 mutation (p.I31T) causing autosomal dominant congenital cataract in a Chinese family. 9 38
20019893 2009
16
Glucose-6-phosphate dehydrogenase (G6PD) deficiency and senile cataract in a Sardinian male population, Italy. 9 38
19995205 2009
17
[Mutation analysis of the PAX6 gene in a family with congenital aniridia and cataract]. 9 38
19806578 2009
18
Synergistic effects of metal ion and the pre-senile cataract-causing G98R alphaA-crystallin: self-aggregation propensities and chaperone activity. 9 38
19862354 2009
19
A novel mutation (F71L) in alphaA-crystallin with defective chaperone-like function associated with age-related cataract. 9 38
19595763 2009
20
Mutations in MYH9 exons 1, 16, 26, and 30 are infrequently found in Japanese patients with nonsyndromic deafness. 9 38
19645626 2009
21
Effects of alpha-crystallin on lens cell function and cataract pathology. 9 38
19860667 2009
22
Age-related cataracts and Prdx6: correlation between severity of lens opacity, age and the level of Prdx 6 expression. 9 38
19429582 2009
23
A novel gammaD-crystallin mutation causes mild changes in protein properties but leads to congenital coralliform cataract. 9 38
19668596 2009
24
Antioxidant status modifications by topical administration of dorzolamide in primary open-angle glaucoma. 9 38
19551670 2009
25
EPHA2 is associated with age-related cortical cataract in mice and humans. 9 38
19649315 2009
26
Founder heterozygous P23T CRYGD mutation associated with cerulean (and coralliform) cataract in 2 Saudi families. 9 38
19633732 2009
27
Aquaporins: translating bench research to human disease. 9 38
19448080 2009
28
Bilateral cataract in a subject carrying a C to A transition in the L ferritin promoter region. 9 38
19254706 2009
29
An alphaA-crystallin gene mutation, Arg12Cys, causing inherited cataract-microcornea exhibits an altered heat-shock response. 9 38
19503744 2009
30
Identification of a novel CRYAB mutation associated with autosomal recessive juvenile cataract in a Saudi family. 9 38
19461931 2009
31
Topical use of coenzyme Q10-loaded liposomes coated with trimethyl chitosan: tolerance, precorneal retention and anti-cataract effect. 9 38
19437594 2009
32
Initiation codon mutation in betaB1-crystallin (CRYBB1) associated with autosomal recessive nuclear pulverulent cataract. 9 38
19461930 2009
33
Deletion of mouse MsrA results in HBO-induced cataract: MsrA repairs mitochondrial cytochrome c. 9 38
19461988 2009
34
Aquaporin water channels in mammals. 9 38
19085041 2009
35
NMR study of the cataract-linked P23T mutant of human gammaD-crystallin shows minor changes in hydrophobic patches that reflect its retrograde solubility. 9 38
19275895 2009
36
Removal of Hsf4 leads to cataract development in mice through down-regulation of gamma S-crystallin and Bfsp expression. 9 38
19224648 2009
37
11p Microdeletion including WT1 but not PAX6, presenting with cataract, mental retardation, genital abnormalities and seizures: a case report. 9 38
19222835 2009
38
Mitochondrial function and redox control in the aging eye: role of MsrA and other repair systems in cataract and macular degenerations. 9 38
18588875 2009
39
Genetics of crystallins: cataract and beyond. 9 38
19007775 2009
40
A new locus for congenital cataract, microcornea, microphthalmia, and atypical iris coloboma maps to chromosome 2. 9 38
19004499 2009
41
Oxidative stress markers in aqueous humor of patients with senile cataracts. 9 38
19172468 2009
42
Structural function of MIP/aquaporin 0 in the eye lens; genetic defects lead to congenital inherited cataracts. 9 38
19096783 2009
43
Novel mutation in the gamma-S crystallin gene causing autosomal dominant cataract. 9 38
19262743 2009
44
Autosomal-dominant cerulean cataract in a chinese family associated with gene conversion mutation in beta-B2-crystallin. 9 38
19321936 2009
45
N-Acetylcarnosine sustained drug delivery eye drops to control the signs of ageless vision: glare sensitivity, cataract amelioration and quality of vision currently available treatment for the challenging 50,000-patient population. 9 38
19503764 2009
46
Disulfide cross-links in the interaction of a cataract-linked alphaA-crystallin mutant with betaB1-crystallin. 9 38
19071118 2009
47
Synergistic effect of osmotic and oxidative stress in slow-developing cataract formation. 9 38
18760274 2008
48
Genistein inhibits aldose reductase activity and high glucose-induced TGF-beta2 expression in human lens epithelial cells. 9 38
18692043 2008
49
A missense mutation in ALDH18A1, encoding Delta1-pyrroline-5-carboxylate synthase (P5CS), causes an autosomal recessive neurocutaneous syndrome. 9 38
18478038 2008
50
Mechanism of insolubilization by a single-point mutation in alphaA-crystallin linked with hereditary human cataracts. 9 38
18700785 2008

Variations for Cataract

ClinVar genetic disease variations for Cataract:

6 (show top 50) (show all 136)
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 IARS2 NM_018060.4(IARS2): c.2726C> T (p.Pro909Leu) single nucleotide variant Pathogenic rs587783070 1:220316451-220316451 1:220143109-220143109
2 RHO NM_000539.3(RHO): c.891C> G (p.Ser297Arg) single nucleotide variant Pathogenic rs142285818 3:129251570-129251570 3:129532727-129532727
3 46;XY;inv(9)(q22.3q34.11)dn inversion Pathogenic
4 LIM2 NM_030657.4(LIM2): c.514C> T (p.Arg172Cys) single nucleotide variant Pathogenic 19:51883831-51883831 19:51380577-51380577
5 COL18A1 NM_030582.4(COL18A1): c.1469-2A> G single nucleotide variant Likely pathogenic rs765919785 21:46897323-46897323 21:45477409-45477409
6 COL18A1 NM_030582.4(COL18A1): c.3979C> T (p.Arg1327Ter) single nucleotide variant Likely pathogenic rs1057518802 21:46929468-46929468 21:45509554-45509554
7 WRN NM_000553.5(WRN): c.724+1G> T single nucleotide variant Likely pathogenic rs1339616347 8:30925844-30925844 8:31068328-31068328
8 COL5A1 NM_000093.4(COL5A1): c.608G> T (p.Gly203Val) single nucleotide variant Likely pathogenic rs1554781700 9:137593133-137593133 9:134701287-134701287
9 EPM2A NM_005670.4(EPM2A): c.376A> G (p.Ile126Val) single nucleotide variant Conflicting interpretations of pathogenicity rs150452237 6:146007358-146007358 6:145686222-145686222
10 PITX2 NM_153427.2(PITX2): c.480A> T (p.Ser160=) single nucleotide variant Conflicting interpretations of pathogenicity rs141176394 4:111539617-111539617 4:110618461-110618461
11 HSF4 NM_001040667.3(HSF4): c.1476C> A (p.Pro492=) single nucleotide variant Conflicting interpretations of pathogenicity rs367756178 16:67203685-67203685 16:67169782-67169782
12 HSF4 NM_001040667.3(HSF4): c.1127T> C (p.Leu376Pro) single nucleotide variant Uncertain significance rs373962350 16:67202778-67202778 16:67168875-67168875
13 HSF4 NM_001040667.3(HSF4): c.*30del deletion Uncertain significance rs756298250 16:67203718-67203718 16:67169815-67169815
14 HSF4 NM_001538.3(HSF4): c.*158_*159dupTT duplication Uncertain significance rs3215366 16:67203835-67203836 16:67169932-67169933
15 XDH NM_000379.4(XDH): c.1172C> T (p.Pro391Leu) single nucleotide variant Uncertain significance 2:31602803-31602803 2:31379937-31379937
16 HSF4 NM_001040667.3(HSF4): c.203T> C (p.Met68Thr) single nucleotide variant Uncertain significance rs751405773 16:67199504-67199504 16:67165601-67165601
17 HSF4 NM_001040667.3(HSF4): c.523C> G (p.Arg175Gly) single nucleotide variant Uncertain significance rs377009893 16:67200260-67200260 16:67166357-67166357
18 HSF4 NM_001040667.3(HSF4): c.741G> A (p.Glu247=) single nucleotide variant Uncertain significance rs373435397 16:67201389-67201389 16:67167486-67167486
19 HSF4 NM_001040667.3(HSF4): c.259G> A (p.Glu87Lys) single nucleotide variant Uncertain significance rs367654370 16:67199648-67199648 16:67165745-67165745
20 HSF4 NM_001040667.3(HSF4): c.394C> T (p.Arg132Cys) single nucleotide variant Uncertain significance rs769736356 16:67199882-67199882 16:67165979-67165979
21 HSF4 NM_001040667.3(HSF4): c.594G> T (p.Ala198=) single nucleotide variant Uncertain significance rs763541172 16:67200493-67200493 16:67166590-67166590
22 MIP NM_012064.4(MIP): c.*1237_*1238dup duplication Uncertain significance rs111463603 12:56843826-56843827 12:56450042-56450043
23 MIP NM_012064.4(MIP): c.*601G> A single nucleotide variant Uncertain significance rs565229690 12:56844463-56844463 12:56450679-56450679
24 MIP NM_012064.4(MIP): c.*132del deletion Uncertain significance rs886049691 12:56844932-56844932 12:56451148-56451148
25 MIP NM_012064.4(MIP): c.493G> A (p.Gly165Ser) single nucleotide variant Uncertain significance rs886049692 12:56847407-56847407 12:56453623-56453623
26 MIP NM_012064.4(MIP): c.361-10C> T single nucleotide variant Uncertain significance rs886049693 12:56847549-56847549 12:56453765-56453765
27 MIP NM_012064.4(MIP): c.98G> A (p.Arg33His) single nucleotide variant Uncertain significance rs139963297 12:56848300-56848300 12:56454516-56454516
28 HSF4 NM_001040667.3(HSF4): c.-191C> G single nucleotide variant Uncertain significance rs769427775 16:67198524-67198524 16:67164621-67164621
29 HSF4 NM_001040667.3(HSF4): c.1137G> A (p.Pro379=) single nucleotide variant Uncertain significance rs369862977 16:67202788-67202788 16:67168885-67168885
30 MIP NM_012064.4(MIP): c.*148dup duplication Uncertain significance rs35639464 12:56844916-56844916 12:56451132-56451132
31 MIP NM_012064.4(MIP): c.*1103C> T single nucleotide variant Uncertain significance rs886049689 12:56843961-56843961 12:56450177-56450177
32 MIP NM_012064.4(MIP): c.*342C> T single nucleotide variant Uncertain significance rs886049690 12:56844722-56844722 12:56450938-56450938
33 HSF4 NM_001538.3(HSF4): c.-759A> G single nucleotide variant Uncertain significance rs777343855 16:67197494-67197494 16:67163591-67163591
34 HSF4 NM_001040667.3(HSF4): c.-354C> A single nucleotide variant Uncertain significance rs886052214 16:67198361-67198361 16:67164458-67164458
35 HSF4 NM_001040667.3(HSF4): c.-186C> T single nucleotide variant Uncertain significance rs772601480 16:67198529-67198529 16:67164626-67164626
36 HSF4 NM_001040667.3(HSF4): c.-23C> T single nucleotide variant Uncertain significance rs760188385 16:67198692-67198692 16:67164789-67164789
37 HSF4 NM_001040667.3(HSF4): c.32A> G (p.Glu11Gly) single nucleotide variant Uncertain significance rs886052215 16:67198746-67198746 16:67164843-67164843
38 HSF4 NM_001040667.3(HSF4): c.1075C> A (p.Pro359Thr) single nucleotide variant Uncertain significance rs886052216 16:67201843-67201843 16:67167940-67167940
39 HSF4 NM_001040667.3(HSF4): c.-565G> A single nucleotide variant Uncertain significance rs147591659 16:67197688-67197688 16:67163785-67163785
40 HSF4 NM_001040667.3(HSF4): c.-448A> G single nucleotide variant Uncertain significance rs886052213 16:67197971-67197971 16:67164068-67164068
41 UPF3B NM_080632.2(UPF3B): c.758T> C (p.Ile253Thr) single nucleotide variant Uncertain significance rs754982440 X:118975088-118975088 X:119841125-119841125
42 CRYGD NM_006891.4(CRYGD): c.295A> G (p.Arg99Gly) single nucleotide variant Uncertain significance rs886055527 2:208986627-208986627 2:208121903-208121903
43 BFSP2 NM_003571.4(BFSP2): c.422A> C (p.Glu141Ala) single nucleotide variant Uncertain significance rs886058009 3:133119349-133119349 3:133400505-133400505
44 BFSP2 NM_003571.4(BFSP2): c.722A> G (p.Tyr241Cys) single nucleotide variant Uncertain significance rs886058012 3:133167482-133167482 3:133448638-133448638
45 CRYGD NM_006891.4(CRYGD): c.482A> G (p.Asn161Ser) single nucleotide variant Uncertain significance rs760434926 2:208986440-208986440 2:208121716-208121716
46 XDH NM_000379.4(XDH): c.3647C> A (p.Pro1216His) single nucleotide variant Uncertain significance rs143981573 2:31562482-31562482 2:31339616-31339616
47 TALDO1 NM_006755.2(TALDO1): c.328A> G (p.Arg110Gly) single nucleotide variant Uncertain significance rs766745943 11:759056-759056 11:759056-759056
48 MMAA NM_172250.3(MMAA): c.304G> A (p.Ala102Thr) single nucleotide variant Uncertain significance rs1328584680 4:146560595-146560595 4:145639443-145639443
49 EPM2A NM_005670.4(EPM2A): c.*1691G> A single nucleotide variant Uncertain significance rs750320097 6:145946861-145946861 6:145625725-145625725
50 BFSP2 NM_003571.4(BFSP2): c.865G> A (p.Glu289Lys) single nucleotide variant Uncertain significance rs145444931 3:133169282-133169282 3:133450438-133450438

Copy number variations for Cataract from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 86882 14 67000000 106368585 Copy number cataract
2 89231 15 17000000 100338915 Copy number cataract
3 106728 17 1 11200000 Copy number cataract

Expression for Cataract

Search GEO for disease gene expression data for Cataract.

Pathways for Cataract

Pathways related to Cataract according to KEGG:

37
# Name Kegg Source Accession
1 Protein processing in endoplasmic reticulum hsa04141

GO Terms for Cataract

Cellular components related to Cataract according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 gap junction GO:0005921 8.96 GJA8 GJA3
2 connexin complex GO:0005922 8.62 GJA8 GJA3

Biological processes related to Cataract according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein homooligomerization GO:0051260 9.62 HSF4 GJA8 CRYAB CRYAA
2 visual perception GO:0007601 9.5 RHO HSF4 GJA3 CRYGD CRYBB3 CRYBA1
3 camera-type eye development GO:0043010 9.46 LIM2 HSF4 GJA8 CRYAB
4 negative regulation of intracellular transport GO:0032387 9.26 CRYAB CRYAA
5 lens development in camera-type eye GO:0002088 9.1 LIM2 GJA8 CRYGS CRYGD CRYBA1 CRYAB

Molecular functions related to Cataract according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 structural constituent of eye lens GO:0005212 9.17 LIM2 CRYGS CRYGD CRYBB3 CRYBA1 CRYAB
2 gap junction channel activity GO:0005243 8.65 GJA8

Sources for Cataract

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....